Alamifovir
| Code | Size | Price |
|---|
| TAR-T25023-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T25023-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T25023-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Alamifovir is an HBV-specific antiviral compound.
CAS:
193681-12-8
Formula:
C19H20F6N5O5PS
Molecular Weight:
575.42
Purity:
0.98
SMILES:
COc1ccc(Sc2nc(N)nc3n(CCOCP(=O)(OCC(F)(F)F)OCC(F)(F)F)cnc23)cc1
References
1. Zhang P, Guo J, Meng F, Sun L, Zhong B, Zhao Y. Determination of alamifovir disoproxil fumarate and its active metabolite 602076 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. J Pharm Biomed Anal. 2012 Mar 5;61:70-7. doi: 10.1016/j.jpba.2011.11.031. Epub 2011 Dec 6. PubMed PMID: 22196804.
2. Yamada H, Suryanarayanan R. X-ray powder diffractometry of intact film coated tablets--an approach to monitor the physical form of the active pharmaceutical ingredient during processing and storage. J Pharm Sci. 2007 Aug;96(8):2029-36. PubMed PMID: 17541977.
3. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE 4th. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther. 2005;10(5):625-33. PubMed PMID: 16152756.
4. Chan C, Abu-Raddad E, Golor G, Watanabe H, Sasaki A, Yeo KP, Soon D, Sinha VP, Flanagan SD, He MM, Wise SD. Clinical pharmacokinetics of alamifovir and its metabolites. Antimicrob Agents Chemother. 2005 May;49(5):1813-22. PubMed PMID: 15855501; PubMed Central PMCID: PMC1087642.